Therapy Areas: Oncology
Biovica names new SVP Business Development
9 December 2019 -

Biovica, a company active in cancer diagnostics, announced on Friday that it has named Henrik Winther as SVP Business Development and as part of the management team.

Winther most recently held the role of SVP Precision Diagnostics at Immunovia. He has earlier worked as global VP of Business Development at the Danish diagnostics company Dako and later as general manager of the Companion Diagnostic Division at Agilent Technologies based in California. Earlier in his career, Winther headed the R&D diagnostic reagents development at Dako. Prior to that he was associate professor in anatomy, physiology and cell biology at the University of Copenhagen.

Winther, said, 'For a decade, Companion Diagnostics i.e. patient stratification for the right individualised treatment, has been the focus of the industry. Now, the next very important topic to secure safe and effective treatments within personalised cancer medicine is the monitoring of patient response to therapy. Biovica is in a strong position with its DiviTum test which provides a unique tool to oncologists that allows for a fast, robust and reliable assessment of patients' response to a given treatment. DiviTum really has a great potential as it is already CE marked, has interesting applications, support from key opinion leaders globally and several excellent clinical study results. The pieces are in place to take Biovica to the next level.'